Eli Lilly and Company v. Ranbaxy Laboratories
Rule established
A patent for a pharmaceutical compound (Olanzapine) was held valid. Ranbaxy's challenge on grounds of obviousness and lack of novelty rejected. Process of selection from a known class of compounds can constitute a valid patent if the selection produces unexpected advantages.
Facts
- Eli Lilly held patent for Olanzapine, selected from a class of thienobenzodiazepine compounds
- Prior art disclosed the broader class but not the specific compound
- Ranbaxy sought to manufacture generic Olanzapine and challenged patent validity
- Ranbaxy argued: compound was obvious to a person skilled in the art from prior disclosures
Issue
- Whether selection of a specific compound from a known class constitutes a valid patentable invention.
Held
- Selection patents are valid in India where the selected compound shows unexpected advantages
- Olanzapine's superior efficacy and reduced side effects were not predictable from the class disclosure
- Person skilled in the art could not have arrived at Olanzapine without inventive step
- Patent upheld as valid
Ratio Decidendi
A selection patent is valid where: (a) the selected compound is not specifically disclosed in prior art, (b) the selection produces advantages (efficacy, safety) not predictable from the class disclosure, and (c) the advantages are demonstrated by evidence. Mere membership in a known class does not destroy novelty.
How to use it in an exam
- Authority for validity of selection patents in India
- Useful for Part B on patentable inventions and Section 3
- Key line: "In Eli Lilly v. Ranbaxy (2008), the Delhi HC held that selection of a specific compound from a known class is patentable where the selected compound shows unexpected therapeutic advantages not predictable from the prior art."
Source
Source: 2008 (37) PTC 399 (Del)
This is an educational summary, not the judgment itself. Cite the reported version in professional or academic work.